Fundraising Fox
/Companies
Sign in

Inhalon Biopharma

Carrboro, US · Founded 2018 · Delaware corporation · 4 known investors

Find your way into Inhalon Biopharma

Sign up to see every warm intro you have to Inhalon Biopharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Inhalon Biopharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Inhalon Biopharma is a clinical-stage biotechnology company developing inhaled "muco-trapping" antibody treatments for acute respiratory infections, including RSV, influenza, human metapneumovirus, and SARS-CoV-2. Its therapies aim to treat active infection directly in the lung.

Also known as Inhalon

BiotechHealthtech

Founders & leadership

Inhalon Biopharma was founded in 2018 by Sam Lai.

SLSam Lai
Sam LaiFounder, Chief Scientific Officer and Director
JW
John WhelanPresident, Chief Executive Officer and DirectorJohn Whelan is a pharmaceutical and biotechnology executive with more than two decades of experience in life sciences company management, including roles in startup leadership, corporate turnarounds, and cross-functional oversight of R&D, manufacturing, clinical operations, and regulatory affairs. He has expertise spanning small molecule and biologic therapeutics, drug delivery technologies, and oncology.
WW
Winnie WanNamed on SEC filing

Investors · 4

Flucas Ventureslisted by Flucas VenturesJupiter · $100K – $5Mvia Ashley Flucas · inferred

How we know: the VCSheet dataset · Not right? Tell us

Sand Hill Angelslisted by Sand Hill AngelsMenlo Park · $50K – $2M
SCP Ventures, LLClisted by SCP Ventures, LLC

Reported raises · per SEC filings

Form D private placements

$2.9M disclosed across 1 round · 2020

▶$2.9MraisedSep 2020 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John B. WhelanExecutive Officer, Director
  • Winnie WanDirector
  • Samuel LaiExecutive Officer, Director
Offering amount
$3.6M
Amount sold
$2.9M
Placement agents
Kim, Hyun Tae
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Company profile

researched Aug 2026

Inhalon Biopharma is a clinical-stage biotechnology company built around an inhaled drug platform intended for the treatment of patients with acute respiratory infections. Named indications include respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza and SARS-CoV-2.

The company is advancing a pipeline of proprietary inhaled antibody treatments, positioned by the company as fast-acting and suitable for at-home administration. Inhalon describes the intended clinical use case as a simplified "test-to-treat" model for respiratory care.

▸Full profile — market position, technology, go-to-market

Market position

Positions itself as developing a new standard of respiratory care through inhaled antibody treatments aimed at superior effectiveness and at-home convenience relative to existing respiratory care approaches.

Differentiation is based on inhaled, fast-acting delivery of antibody treatments directly to the lungs rather than systemic administration, enabling at-home dosing and a test-to-treat treatment pathway.

Technology

The company's approach centers on an inhaled drug delivery platform for antibody therapeutics, described by the company as precedent-setting, that delivers proprietary antibodies directly to the respiratory tract to act against acute respiratory viral infections including RSV, hMPV, influenza and SARS-CoV-2.

Go-to-market

Patients suffering from acute respiratory infections, with an emphasis on at-home treatment convenience following diagnosis under a test-to-treat model.

Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.

Related companies · 4

Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
Avalyn Pharma IncAvalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.
EledonEledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.
Lantern PharmaLantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.

Companies working in the same space as Inhalon Biopharma.

Legal entities · 1

corporate structure
Inhalon BiopharmaDelaware

▸Research sources · 1

primary sources listed

1 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Inhalon Biopharma do?
Clinical-stage biotech developing inhaled antibody treatments for acute respiratory infections such as RSV, hMPV and influenza.
Who founded Inhalon Biopharma?
Inhalon Biopharma was founded by Sam Lai in 2018.
Who are Inhalon Biopharma's investors?
Inhalon Biopharma's investors include Berkeley Catalyst, Flucas Ventures, Sand Hill Angels, SCP Ventures, LLC.
How much funding has Inhalon Biopharma raised?
Inhalon Biopharma has disclosed $2.9M raised across 1 round.
Where is Inhalon Biopharma headquartered?
Inhalon Biopharma is headquartered in Carrboro, US.